ArticleTranslational pediatrics2026
Construction of a predictive model for lower respiratory tract infection in children with leukemia after chimeric antigen receptor T cell therapy.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chimeric antigen receptor T (CAR-T) cells have achieved breakthrough results in the treatment of refractory/relapsed leukemia in children. With the continuous development of research and increasing clinical application, infection events after CAR-T cell therapy have gradually attracted the attention of researchers. Lower respiratory tract infection (LRTI) events accounted for 19.2% of the total number of infection events and resulted in patient death. This study aims to investigate the risk factors of LRTI in children with leukemia who received CAR-T cell therapy and construct a risk predictive model. Methods: The clinical data of children with leukemia receiving CAR-T cell therapy in a tertiary A children's hospital in Shanghai from November 2023 to December 2024 were retrospectively collected, and the independent risk factors for LRTI were analyzed, and a risk predictive model was constructed. The Hosmer-Lemeshow test and the area under the receiver operating characteristic (ROC) curve were used to evaluate the fitting degree and discrimination of the predictive model, and a nomogram was constructed to visualize the model. Results: A total of 265 cases were included in this study, and the incidence of LRTI within 0-30 days after CAR-T cell therapy was 14.7%. The risk factors for developing LRTI were platelet count (PLT) <50×10 Conclusions: In this study, a risk predictive model for LRTI in children with leukemia within 0-30 days after CAR-T cell therapy was constructed. The predictive factors were PLT <50×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.